In Brief: Shingrix for Immunocompromised Adults
Date: August 23, 2021
Issue #:
1631Summary:
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccineShingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk because of disease-
or therapy-induced immunodeficiency or immunosuppression.Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1
It is the only VZV vaccine currently available in the US;Zostavax, a live-attenuated VZV vaccine, was withdrawn
from the market in 2020.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Shingles Shingrix vaccines varicella zoster virus Source Type: research
More News: Drugs & Pharmacology | Herpes | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine